2
BRCA1/BRCA2 gene
Micro Solutions / Life Science
NGS test of hereditary breast and ovarian cancer: BRCA1 and BRCA2 genes
NGS test of hereditary breast and ovarian cancer: BRCA1 and BRCA2 genes
for blood samples and FFPE tissue, sequencing on the Illumina MiSeq platform
The BRCAaccuTest PLUS NGS test detects BRCA1 and BRCA2 gene mutations from blood and FFPE tissue samples, helping to assess the risk of hereditary breast and ovarian cancer.
The next-generation sequencing test system identifies pathogenic variants in BRCA1 and BRCA2 genes in genomic DNA from blood or tumor FFPE tissue samples. Sequencing is performed on Illumina MiSeq devices with an average coating of about 200× for germinal and 1,000× for somatic samples. NGeneAnalySys, which forms a clinical report.
The BRCAaccuTest PLUS panel covers the BRCA1 and BRCA2 genes. Diagnostic efficacy was confirmed in a sample of 108 samples - the results are more than 99% matched.
BRCA1/BRCA2 gene
certification
somatication
diagnostic match
| Genes | BRCA1, BRCA2 |
|---|---|
| Type of sample | genomic DNA from blood or FFPE tissue |
| Average coverage | ~200× (germinal samples); ~1,000× (somatic samples) |
| Clinical validation | 108 samples, diagnostic match over 99% |
| Sequencing | Illumina MiSeq |
|---|---|
| Analysis | NGeneAnalySys |
| Status | CE-IVD |
|---|